secwatch.observer — SEC 8-K summary
======================================

Issuer:     BIOMARIN PHARMACEUTICAL INC (BMRN)
CIK:        0001048477
Form:       8-K
Filed at:   2026-01-29T23:59:59+00:00
Accession:  0001193125-26-029401
Event type: debt
Sentiment:  neutral
Materiality: 0.75
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

BioMarin prices $850M 5.500% notes due 2034 and syndicates $2B term loan for Amicus acquisition
--------------------------------------------------------------------------------

- $850M 5.500% senior notes due 2034; price 100%; expected close Feb 12, 2026.
- Syndicated $2B term loan B, plus $800M term loan A and $600M revolver for pending Amicus acquisition.
- Proceeds from notes and term loans, plus cash on hand, to fund Amicus acquisition consideration and fees.
- If acquisition not completed by Dec 19, 2026, notes subject to special mandatory redemption at 100% plus accrued interest.
- Notes guaranteed by BioMarin subsidiaries including Amicus post-closing; covenants limit debt, dividends, liens.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1048477/000119312526029401/0001193125-26-029401-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1048477/000119312526029401/d170996d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-029401

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer